James Falko, MD
Endocrinology, Diabetes & Metabolism · Aurora, CONPI 1669460887
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,625 of the $44,959 with a category attached, or 65.9%. Kowa Pharmaceuticals America, Inc. accounts for 71.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $15,057 and has fallen 97.9% since, to $323 in 2025. Among endocrinology, diabetes & metabolism clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $576.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kowa Pharmaceuticals America, Inc.$32K
- Regeneron Healthcare Solutions, Inc.$6K
- Merck$5K
- Amgen$389
- Kaneka Medical America LLC$314
- Regeneron$203
- plus $748 from 6 others
What the payments were for
- Consulting fees$5,30412%
- Speaking & faculty fees$29,62566%
- Travel & lodging$6,69115%
- Food & beverage$3,3197%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kowa Pharmaceuticals America, Inc. | 33 | $32,332 |
| Regeneron Healthcare Solutions, Inc. | 11 | $6,351 |
| Merck | 7 | $4,622 |
| Amgen | 10 | $389 |
| Kaneka Medical America LLC | 2 | $314 |
| Regeneron | 2 | $203 |
| Amarin Pharma, Inc. | 6 | $195 |
| Heartflow, Inc. | 3 | $193 |
| Cleerly, Inc. | 1 | $130 |
| Akcea Therapeutics, Inc. | 1 | $129 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Livalo$15,047
- EVKEEZA$6,164
- STEGLATRO$4,622
- Repatha$246
- FFRct$149
- Seglentis$131
- Cleerly Ischemia$130
- Cleerly Labs$130
- TEGSEDI$129
- Vascepa$121
- ATRIAL FIBRILLATION - DISEASE$100
How this compares
$44,959 in reported general payments places this provider in the 90th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 36 | $35,866 |
| Praluent PenAlirocumab | 18 | $25,577 |
| Ezetimibe | 26 | $945 |
| Atorvastatin Calcium | 16 | $86 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Aurora
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Halis AkturkAurora$109K
- Robert EckelAurora$66K
- Marc Andre CornierAurora$62K
- Jane ReuschAurora$59K
- Aaron MichelsAurora$37K
- Margaret WiermanAurora$36K
- Peter GottliebAurora$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.